Positive response to trastuzumab deruxtecan in a patient with HER2-mutant NSCLC after multiple lines therapy, including T-DM1: a case report

Positive response to trastuzumab deruxtecan in a patient with HER2-mutant NSCLC after multiple lines therapy, including T-DM1: a case report

Human epidermal growth factor 2 (HER2) mutations are uncommon in non-small cell lung cancer (NSCLC), and the lack of established, effective, targeted drugs has resulted in a persistently poor prognosis. Herein, we report the case of a non-smoking, 58-year-old man diagnosed with lung adenocarcinoma (...

Full description

Bibliographic Details
Main Authors: Junzhu Xu, Bo He, Yunan Wang, Mengjia Wu, Yanyi Lu, Zixuan Su, Shujun Liu, Fengmin Yin, Jian-Guo Zhou, Wei Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Oncology
Subjects:
HER2 mutation
non-small cell lung cancer
chemotherapy
target-therapy
T-DXd
ADCS
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1268260/full

Similar Items

Similar Items